CN103120644B - 生物功能性蛋白大分子的两亲嵌段共聚物胶束及其制备和应用 - Google Patents
生物功能性蛋白大分子的两亲嵌段共聚物胶束及其制备和应用 Download PDFInfo
- Publication number
- CN103120644B CN103120644B CN201210455274.0A CN201210455274A CN103120644B CN 103120644 B CN103120644 B CN 103120644B CN 201210455274 A CN201210455274 A CN 201210455274A CN 103120644 B CN103120644 B CN 103120644B
- Authority
- CN
- China
- Prior art keywords
- micelle
- medicative
- protein macromolecule
- biofunctional
- epo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000693 micelle Substances 0.000 title claims abstract description 129
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 59
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 59
- 229920002521 macromolecule Polymers 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 229920000469 amphiphilic block copolymer Polymers 0.000 title claims abstract description 13
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims abstract description 63
- 102000003951 Erythropoietin Human genes 0.000 claims abstract description 53
- 108090000394 Erythropoietin Proteins 0.000 claims abstract description 53
- 229940105423 erythropoietin Drugs 0.000 claims abstract description 53
- 239000003814 drug Substances 0.000 claims abstract description 29
- 229920000642 polymer Polymers 0.000 claims abstract description 17
- 102000014150 Interferons Human genes 0.000 claims abstract description 8
- 108010050904 Interferons Proteins 0.000 claims abstract description 8
- 229940079322 interferon Drugs 0.000 claims abstract description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 34
- 238000003756 stirring Methods 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 20
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 14
- 230000002209 hydrophobic effect Effects 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 8
- 229940022353 herceptin Drugs 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 230000008827 biological function Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- -1 polyacrylic Polymers 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000000975 bioactive effect Effects 0.000 claims description 2
- 229920001519 homopolymer Polymers 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 40
- 239000002245 particle Substances 0.000 abstract description 23
- 238000002347 injection Methods 0.000 abstract description 9
- 239000007924 injection Substances 0.000 abstract description 9
- 238000004108 freeze drying Methods 0.000 abstract description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 229920001553 poly(ethylene glycol)-block-polylactide methyl ether Polymers 0.000 description 31
- 239000011550 stock solution Substances 0.000 description 21
- 238000005374 membrane filtration Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 102000001554 Hemoglobins Human genes 0.000 description 9
- 108010054147 Hemoglobins Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 239000000539 dimer Substances 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000006471 dimerization reaction Methods 0.000 description 6
- 210000001995 reticulocyte Anatomy 0.000 description 6
- 229920000375 Poly(ethylene glycol)-block-poly(ε−caprolactone) methyl ether Polymers 0.000 description 5
- 229920000471 Poly(ethylene oxide)-block-polylactide Polymers 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940040591 biotech drug Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210455274.0A CN103120644B (zh) | 2011-11-17 | 2012-11-13 | 生物功能性蛋白大分子的两亲嵌段共聚物胶束及其制备和应用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110364172 | 2011-11-17 | ||
CN201110364172.3 | 2011-11-17 | ||
CN2011103641723 | 2011-11-17 | ||
CN201210455274.0A CN103120644B (zh) | 2011-11-17 | 2012-11-13 | 生物功能性蛋白大分子的两亲嵌段共聚物胶束及其制备和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103120644A CN103120644A (zh) | 2013-05-29 |
CN103120644B true CN103120644B (zh) | 2016-12-21 |
Family
ID=48451916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210455274.0A Active CN103120644B (zh) | 2011-11-17 | 2012-11-13 | 生物功能性蛋白大分子的两亲嵌段共聚物胶束及其制备和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103120644B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103739705A (zh) * | 2014-01-02 | 2014-04-23 | 辽宁迈迪生物科技有限公司 | 一种抗体亲和纯化的洗脱新方法及其应用 |
CN107603241B (zh) * | 2017-09-25 | 2019-09-13 | 中原工学院 | 一种梭形纳米胶束的制备方法 |
CN108333198A (zh) * | 2018-03-15 | 2018-07-27 | 长春黄金研究院有限公司 | 一种高效准确的观测高温下嵌段共聚物胶束形貌的方法 |
CN113248724B (zh) * | 2021-04-13 | 2023-06-02 | 康汉医药(广州)有限公司 | 一种蛋白药物固体制剂及其制备方法 |
CN113248723B (zh) * | 2021-04-13 | 2023-06-02 | 康汉医药(广州)有限公司 | 一种蛋白药物缓释制剂的制备方法 |
CN113264997B (zh) * | 2021-04-13 | 2023-07-04 | 康汉医药(广州)有限公司 | 一种蛋白药物在常温、高温条件下保存的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101224187A (zh) * | 2008-01-31 | 2008-07-23 | 中国医学科学院生物医学工程研究所 | 双功能聚合物纳米胶束及制备方法及在制备治疗血管再狭窄药物中的应用 |
CN101773465A (zh) * | 2010-01-19 | 2010-07-14 | 南京泛太化工医药研究所 | 以氨基酸为稳定剂的聚合物胶束载药系统 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE531391T1 (de) * | 2004-05-06 | 2011-11-15 | Samyang Corp | Abgabesystem für biologisch wirksame mittel auf basis eines polymeren arzneiträgers mit einem ampiphilen blockpolymer und einem polymilchsäure- derivat |
US8147868B2 (en) * | 2006-07-18 | 2012-04-03 | Nanocarrier Co., Ltd. | Physiologically active polypeptide- or protein-encapsulating polymer micelles, and method for production of the same |
ES2351484B2 (es) * | 2009-07-24 | 2011-10-11 | Universidad De Santiago De Compostela | Micelas pic dendriticas con proteinas bioactivas. |
CN101972480B (zh) * | 2010-01-19 | 2013-01-02 | 南京泛太化工医药研究所 | 以氨基酸为稳定剂的聚合物胶束载药系统 |
-
2012
- 2012-11-13 CN CN201210455274.0A patent/CN103120644B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101224187A (zh) * | 2008-01-31 | 2008-07-23 | 中国医学科学院生物医学工程研究所 | 双功能聚合物纳米胶束及制备方法及在制备治疗血管再狭窄药物中的应用 |
CN101773465A (zh) * | 2010-01-19 | 2010-07-14 | 南京泛太化工医药研究所 | 以氨基酸为稳定剂的聚合物胶束载药系统 |
Also Published As
Publication number | Publication date |
---|---|
CN103120644A (zh) | 2013-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103120644B (zh) | 生物功能性蛋白大分子的两亲嵌段共聚物胶束及其制备和应用 | |
Azmi et al. | Cubosomes and hexosomes as versatile platforms for drug delivery | |
US9339553B2 (en) | Liquid compositions of insoluble drugs and preparation methods thereof | |
JP4890732B2 (ja) | 癌治療用パクリタキセル・リポソーム組成物およびその製造方法 | |
KR102203555B1 (ko) | 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도 | |
DK2750667T3 (en) | DEPOTLIPID CONCENTRATE OF PHARMACOLOGICAL ACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION, INCLUDING THIS | |
JP5127466B2 (ja) | 医薬脂質組成物 | |
NO333811B1 (no) | Stealth-nanokapsler, fremgangsmåter for fremstilling derav og anvendelse som en bærer for aktivt prinsipp/aktive prinsipper | |
JP2004514734A (ja) | 疎水性薬物の徐放性デリバリー用組成物及びその製造方法 | |
JP2007517023A (ja) | 水溶性薬物を含有する経口投与用ナノ粒子組成物及びその製造方法 | |
WO2010083778A1 (zh) | 注射用肺靶向脂质体药物组合物 | |
CN106822039A (zh) | 水难溶或微溶性药物缓释组合物及其制备方法 | |
TW200904483A (en) | Proliposomal and liposomal compositions of poorly water soluble drugs | |
CN109771663B (zh) | 一种酸响应性抗癌纳米药物的制备及应用 | |
CN101322682A (zh) | 难溶性药物纳米粒的制备方法 | |
CN103893123B (zh) | 一种脂质体-聚合物杂化纳米粒子及其制备方法和应用 | |
US9265728B2 (en) | Biocompatible particles and method for preparing same | |
US10792244B2 (en) | Parenteral sustained-release delivery of carvedilol disperse systems | |
WO2021057007A1 (zh) | 一种雷帕霉素纳米缓释剂及其制备方法 | |
JP2006500387A (ja) | 固形ナノ医薬およびその調製方法 | |
CN106822042A (zh) | 一种利培酮缓释组合物及其制备方法 | |
CN1973832B (zh) | 具有ct示踪效应的可生物降解纳米药物胶囊及其制备方法 | |
CN106727589A (zh) | 帕利哌酮及其衍生物的缓释组合物与该缓释组合物的制备方法 | |
Binaymotlagh et al. | Liposome–Hydrogel Composites for Controlled Drug Delivery Applications | |
Karimi et al. | Prolonged local delivery of doxorubicin to cancer cells using lipid liquid crystalline system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: 264003 Yantai hi tech Zone, Shandong venture Road No. 15 Applicant after: Shandong Luye Pharma Co., Ltd. Applicant after: Nanjing Luye Pharmaceutical Co., Ltd. Address before: 264003 Laishan, Shandong Province Bao Road, No. 9 District, No. Applicant before: Shandong Luye Pharma Co., Ltd. Applicant before: Nanjing Luye Pharmaceutical Co., Ltd. |
|
CB02 | Change of applicant information |
Address after: 264003 Yantai hi tech Zone, Shandong venture Road No. 15 Applicant after: Shandong Luye Pharma Co., Ltd. Applicant after: NANJING LVYE PHARMA CO., LTD. Address before: 264003 Yantai hi tech Zone, Shandong venture Road No. 15 Applicant before: Shandong Luye Pharma Co., Ltd. Applicant before: Nanjing Luye Pharmaceutical Co., Ltd. |
|
COR | Change of bibliographic data | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200608 Address after: 264670 No. 39, science and technology Avenue, hi tech Zone, Shandong, Yantai Patentee after: SHANDONG BIOANTY BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: 264003, No. 15, pioneering Road, hi tech Zone, Shandong, Yantai Co-patentee before: NANJING LUYE PHARMA Co.,Ltd. Patentee before: Shandong Luye Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: 264670 No. 39 Science and Technology Avenue, Yantai High-tech Zone, Shandong Province Patentee after: Shandong Boan Biotechnology Co.,Ltd. Address before: 264670 No. 39 Science and Technology Avenue, Yantai High-tech Zone, Shandong Province Patentee before: SHANDONG BIOANTY BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |